Shin Kasai

Shin Kasai

Auto-generated profile, based on publicly available information

Shin Kasai

Department of Pediatrics, School of Medicine University of Yamanashi Chuo Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Leukemia Research
Verified
Journal Article
Closed access
NANorie Ando
Norie Ando
YFYoshiyuki Furuichi
Yoshiyuki Furuichi
SKShin Kasai
Shin Kasai
MTMinori Tamai
Minori Tamai
DHDaisuke Harama
Daisuke Harama
KSKanji Sugita
Kanji Sugita

6 May 2022 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
TNThao T. T. Nguyen
Thao T. T. Nguyen
MTMinori Tamai
Minori Tamai
DHDaisuke Harama
Daisuke Harama
KKKeiko Kagami
Keiko Kagami
SKShin Kasai
Shin Kasai
TITakeshi Inukai
Takeshi Inukai

12 January 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
SKShin Kasai
Shin Kasai
MTMinori Tamai
Minori Tamai
ESEiji Sugihara
Eiji Sugihara
NONaoki Oishi
Naoki Oishi
KHKyoko Hinata
Kyoko Hinata
TITakeshi Inukai
Takeshi Inukai

1 January 2025 in Pediatrics International
Verified
Journal Article
Closed access
SKShin Kasai
Shin Kasai
MTMari Tsukahara
Mari Tsukahara
AWAtsushi Watanabe
Atsushi Watanabe
KAKoshi Akahane
Koshi Akahane
MWMasanori Wako
Masanori Wako
TITakeshi Inukai
Takeshi Inukai

13 October 2026 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
TNThao T. T. Nguyen
Thao T. T. Nguyen
MTMinori Tamai
Minori Tamai
KAKoshi Akahane
Koshi Akahane
CKChiaki Komatsu
Chiaki Komatsu
KKKeiko Kagami
Keiko Kagami
TITakeshi Inukai
Takeshi Inukai
TP53 mutations are linked to poor prognoses in B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), indicating that specific p53 target genes may contribute to drug resistance. Although the impact of specific genetic alterations on drug sensitivity has been reported in BCP‐ALL, the effects of TP53 mutations on sensitivity to individual agents remain poorly defined in the clinical setting because of the use of combination chemotherapy regimens. In the present study, we addressed this issue through two complementary analyses using a large panel of BCP‐ALL cell lines. Initially, 30 cell lines harboring TP53 mutations demonstrated significantly greater resistance to daunorubicin (DNR), mafosfamide (MAF; an active analog of cyclophosphamide), 6‐mercaptopurine (6‐MP), and prednisolone compared to 46 cell lines without mutations. Second, 11 CRISPR/Cas9‐mediated TP53 ‐knockout sublines derived from cell lines with wild‐type TP53 recapitulated resistance to DNR, MAF, and 6‐MP, as well as to vincristine (VCR) and cytarabine (Ara‐C). Consistent with these findings, re‐evaluation of genome‐wide CRISPR screening datasets revealed significant enrichment of TP53 gRNAs in cells treated with DNR, MAF, 6‐MP, Ara‐C, and VCR. Furthermore, transcriptomic and proteomic analyses of p53 target genes in the two cell line models, along with re‐evaluation of genome‐wide CRISPR screening datasets, identified BAX , BBC3 , and FDXR as key p53 target genes associated with multidrug resistance. These results highlight the potential value of targeting these p53 downstream pathways to improve outcomes in TP53 ‐mutated BCP‐ALL cases.